Home › Funds › Bain Capital Life Sciences Investors, LLC › CABA
Bain Capital Life Sciences Investors, LLC position in CABA
CABALETTA BIO INC · Health Care
Bain Capital Life Sciences Investors, LLC reported holding 21,209,188 shares of CABA (CABALETTA BIO INC) in its Q3 2026 13F filing — a position valued at US$40.7M, representing 2.80% of its reported portfolio and ranking #12 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed CABA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Bain Capital Life Sciences Investors, LLC's CABA position evolved
Bain Capital Life Sciences Investors, LLC first disclosed a stake in CABA in Q3 2023 at 2,000,000 shares (US$30.4M). The position peaked in Q2 2026 at 17,241,445 shares, worth US$53.6M. Across 13 filings, Bain Capital Life Sciences Investors, LLC increased the stake 5 time(s), trimmed it 1 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 21,209,188 shares valued at US$40.7M — an increase of 3,967,743 shares quarter over quarter.. Notable position changes include a 67% increase in Q3 2024 (shares fell 52% over the following quarter), a 251% increase in Q2 2025 (shares rose 54% over the following quarter), a 78% increase in Q2 2026 (shares fell 38% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.00M | $30.44M | New |
| Q4 2023 | 2.00M | $45.40M | Hold |
| Q1 2024 | 1.62M | $27.59M | Reduce |
| Q2 2024 | 1.65M | $12.34M | Add |
| Q3 2024 | 2.76M | $13.03M | Add |
| Q4 2024 | 2.76M | $6.27M | Hold |
| Q1 2025 | 2.76M | $3.82M | Hold |
| Q2 2025 | 9.68M | $14.71M | Add |
| Q3 2025 | 9.68M | $22.64M | Hold |
| Q4 2025 | 9.68M | $21.19M | Hold |
| Q1 2026 | 9.68M | $26.03M | Hold |
| Q2 2026 | 17.24M | $53.62M | Add |
| Q3 2026 | 21.21M | $40.72M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CABA and 13F data
CABA (CABALETTA BIO INC) is a Health Care company. 33 other funds we track also report a position in CABA — the largest reported positions include Cormorant Asset Management, LP (US$15.6M), Opaleye Management Inc. (US$12.0M), Propel Bio Management, LLC (US$3.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CABA
- Cormorant Asset Management, LP 5.00M sh · $15.55M · Q2 2026
- Opaleye Management Inc. 3.86M sh · $12.02M · Q2 2026
- Propel Bio Management, LLC 2.05M sh · $3.93M · Q3 2026
- Occam Crest Management LP 1.19M sh · $2.28M · Q3 2026
More on Bain Capital Life Sciences Investors, LLC
FAQ
How long has Bain Capital Life Sciences Investors, LLC held CABA?
Bain Capital Life Sciences Investors, LLC has disclosed CABA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Bain Capital Life Sciences Investors, LLC's current position in CABA?
As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 21.21M shares of CABA (CABALETTA BIO INC), valued at $40.72M, representing 2.80% of its reported portfolio and ranking #12.
Has Bain Capital Life Sciences Investors, LLC been buying or selling CABA?
In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC increased its position in CABA. The position peaked in Q2 2026 at 17.24M shares.
Which other funds hold CABA?
Other major institutional holders of CABA include Cormorant Asset Management, LP, Opaleye Management Inc., Propel Bio Management, LLC, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.